Search results

1. ESMO 2025 preview – first clinical results

   … G12D asset HRS-4642, whose 6% ORR was a big letdown at ESMO 2023 . What stands out especially regarding the new …

   
    

   Jacob Plieth
    
   - 10/13/2025 - 16:26

2. Zelgen’s DLL3 trispecific goes pivotal

   … Harpoon) Ph1/2  data in 2nd-line solid tumours at ESMO 2023: ORR 35% across tumour types; ifinatamab-dxd combo …

   
    

   Madeleine Armstrong
    
   - 10/02/2025 - 14:19

3. HengRui presses on in HER3, despite Merck’s failure

   … go on so far. In a phase 1 solid tumour trial presented at ESMO 2023 ruza-can produced an ORR of 30% among 30 NSCLC …

   
    

   Madeleine Armstrong
    
   - 09/25/2025 - 12:14

4. DLL3 goes trispecific

   … Harpoon) Ph1/2 data in 2nd-line solid tumours at ESMO 2023: ORR 35% across tumour types; ifinatamab-dxd combo …

   
    

   Madeleine Armstrong
    
   - 09/29/2025 - 12:49

5. NextCure joins Merck in an ovarian target

   … Ph3 Rejoice-Ovarian01 completes Dec 2027; ph1 data at ESMO 2023: cORR 46% (23/50) in ovarian cancer* CUSP06 …

   
    

   Madeleine Armstrong
    
   - 06/19/2025 - 11:19

6. Lepu starts another pivotal conjugate trial

   … similar setting will feature in a late-breaking session. At ESMO 2023 the same phase 2 produced ORRs of 39% and 55% with …

   
    

   Madeleine Armstrong
    
   - 05/22/2025 - 13:39

7. Novartis gets a PSMAfore green flag at last

   … or a different androgen-receptor-targeting therapy. At ESMO 2023 it became apparent that, although the study had …   Final analysis 2nd interim analysis  (ESMO 2023) Crossover 60% 84% OS HR … 0.38-0.91 0.48-1.33 Source: company releases & ESMO 2023.   This was clearly enough for the FDA; the …

   
    

   Madeleine Armstrong
    
   - 04/01/2025 - 16:46

8. ELCC 2025 – BioNTech impresses in small-cell lung

   … 42% – lower than the 73% reported from the same study at ESMO 2023. Still, the result is in line with the 40% ORR …

   
    

   Madeleine Armstrong
    
   - 04/01/2025 - 16:09

9. AACR 2025 preview – distressed biotechs seek redemption

   … Ph1 low-dose irinotecan combo Had monoRx data at ESMO 2023 D3S-001 KRAS G12C inhibitor D3 Bio …

   
    

   Jacob Plieth
    
   - 03/28/2025 - 08:55

10. Imfinzi puts its flag on the Matterhorn

    … already read out positively for pCR, with data presented at ESMO 2023, but the trial remained blinded for EFS, and it's … PD-L1 at a level of at least 1%. It will be noted that ESMO 2023 showed Matterhorn's pCR benefit to be strongest in …

    
     

    Jacob Plieth
     
    - 03/11/2025 - 15:11